The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

 

Sanofi SA

NYSE: SNY
Last

(U.S.) $49.28

Today's change-0.80 -1.60%
Updated August 28 4:02 PM EDT. Delayed by at least 15 minutes.
 

Sanofi SA

NYSE: SNY
Last

(U.S.) $49.28

Today's change-0.80 -1.60%
Updated August 28 4:02 PM EDT. Delayed by at least 15 minutes.

Sanofi SA crosses below 200-day moving average

Sanofi SA closed sharply lower Friday, dropping (U.S.)$0.80 or 1.60% to (U.S.)$49.28 and crossing below its 200-day moving average. Shares have lost 0.46% over the last five days, but have gained 8.05% over the last year to date. This security has underperformed the S&P 500 by 9.51% during the last year.

Key company metrics

  • Open(U.S.) $49.51
  • Previous close(U.S.) $50.08
  • High(U.S.) $49.70
  • Low(U.S.) $49.16
  • Bid / Ask-- / --
  • YTD % change+8.05%
  • Volume1,091,901
  • Average volume (10-day)1,858,074
  • Average volume (1-month)1,379,961
  • Average volume (3-month)1,725,537
  • 52-week range(U.S.) $43.57 to (U.S.) $57.42
  • Beta1.17
  • Trailing P/E23.96×
  • P/E 1 year forward15.55×
  • Forward PEG1.75×
  • Indicated annual dividend(U.S.) $1.61
  • Dividend yield3.27%
  • Trailing EPS(U.S.) $2.06
Updated August 28 4:02 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+14.00%

Based on its net profit margin of 14.00%, Sanofi SA is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.71%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q2/2015Q1/2015Q4/2014Q3/2014
Fiscal Quarter Endvalues in $ millions unless otherwise notedJun 30, 201506/30/2015Mar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014
Revenue9,4618,8909,1708,868
Total other revenue--------
Total revenue9,4618,8909,1708,868
Gross profit6,5236,1046,1296,004
Total cost of revenue2,9382,7863,0412,864
Total operating expense7,4667,4877,4857,084
Selling / general / administrative2,6482,4382,4652,309
Research & development1,2901,1991,3511,146
Depreciation / amortization611618620561
Interest expense (income), net operating--------
Unusual expense (income)2938018158
Other operating expenses, total-5066-1046
Operating income1,9951,4031,6851,784
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax1,8831,3061,5471,645
Income after tax1,3641,0861,3811,264
Income tax, total519220166381
Net income1,3021,0231,3391,190
Total adjustments to net income--------
Net income before extra. items1,3021,0231,3391,190
Minority interest-27-32-27-31
Equity in affiliates-35-31-15-43
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items1,3021,0231,3391,190
Inc. avail. to common incl. extra. items1,3021,0231,3391,190
Diluted net income1,3021,0231,3391,190
Dilution adjustment----00
Diluted weighted average shares1,3061,3081,3461,313
Diluted EPS excluding extraordinary itemsvalue per share1.000.780.990.91
Dividends per sharevalue per share0.000.001.580.00
Diluted normalized EPSvalue per share1.011.020.951.07